SU2C-SARC032 trial: Immunotherapy reduces relapse risk in soft tissue sarcoma by 43%

FHS
June 4, 2024
2:12 pm

For the last three decades, breakthroughs have been sparse for soft tissue sarcomas, which are rare cancers that affect muscles, fat and other connective tissues.

COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression – Psychedelic Alpha

LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in

September 6, 2023

Hepatitis C treatment initiation found to be low among Medicaid recipients

While there are highly effective treatments for the hepatitis C virus (HCV), only 1 in 5 Medicaid enrollees diagnosed with HCV started treatment, according to

August 8, 2023

Childhood adversity linked to elevated health risks, differing by sex and stress

Researchers assess the heterogeneous effects of childhood adversity on disease biomarkers and health conditions in adulthood.

September 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.